{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:20:58Z","timestamp":1759666858501},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p>The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double\u2010blind trial. Patients with newly diagnosed mild\u2010to\u2010moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg\/day of torasemide\u2010PR (n = 219) or torasemide\u2010IR (n = 223) for 12 weeks (uptitration to 10 mg\/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide\u2010PR group (11.6 \u00b1 7.1 mmHg, 95% confidence interval [CI] 10.6\u201312.5) <jats:italic>versus<\/jats:italic> torasemide\u2010IR (11.3 \u00b1 7.5 mmHg, 95% CI 10.2\u201312.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide\u2010PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24\u2010h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide\u2010PR group (128.4 \u00b1 9.9 mmHg vs. 133.5 \u00b1 10.4 mmHg, <jats:italic>P<\/jats:italic> &lt; 0.05). Safety and tolerability of both formulations were similar.<\/jats:p>","DOI":"10.1111\/j.1527-3466.2008.00046.x","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T15:42:08Z","timestamp":1207237328000},"page":"91-100","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Effects of Torasemide Prolonged Release in Mild\u2010to\u2010Moderate Hypertension: A Randomized Noninferiority Trial <i>Versus<\/i> Torasemide Immediate Release"],"prefix":"10.1111","volume":"26","author":[{"given":"Alex","family":"Roca\u2010Cusachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Aracil\u2010Vilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Calvo\u2010G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9\u2010Vicente","family":"Vaquer\u2010P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Laporta\u2010Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda\u2010Jos\u00e9","family":"Rojas\u2010Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savion","family":"Gropper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Torasemide\u2010PR in Hypertension Clinical Trial Investigators Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877959"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022273"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549010-00009"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00001"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141010-00008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.29.645"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80044-3"},{"issue":"1","key":"e_1_2_7_10_1","first-page":"48","article-title":"Single\u2010dose, randomized, cross\u2010over bioavailability pilot clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide [abstract]","volume":"99","author":"Gropper S","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"e_1_2_7_11_1","first-page":"48","article-title":"Single and repeated\u2010dose, randomized, cross\u2010over, bioavailability clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide [abstract]","volume":"99","author":"Gropper S","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.570192"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199322003-00005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549020-00002"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005121329"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200112000-00016"},{"key":"e_1_2_7_18_1","unstructured":"The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP)(1999) Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation). CPMP\/EWP\/280\/96 London."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020131"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200311000-00002"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-3466.2008.00046.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-3466.2008.00046.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:20:34Z","timestamp":1696990834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-3466.2008.00046.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1527-3466.2008.00046.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-3466.2008.00046.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"type":"print","value":"1755-5914"},{"type":"electronic","value":"1755-5922"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}